Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition
- PMID: 36307922
- PMCID: PMC9892865
- DOI: 10.1093/ehjcvp/pvac056
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition
Abstract
Aims: Low-density lipoprotein (LDL-C) lowering is imperative in cardiovascular disease prevention. We aimed to compare accuracy of three clinically-implemented LDL-C equations in a clinical trial of cholesterol ester transfer protein (CETP) inhibition.
Methods and results: Men and women aged 18-75 years with dyslipidaemia were recruited from 17 sites in the Netherlands and Denmark. Patients were randomly assigned to one of nine groups using various combinations of the CETP inhibitor TA-8995 (obicetrapib), statin therapy, and placebo. In pooled measurements over 12 weeks, we calculated LDL-C by the Friedewald, Martin/Hopkins, and Sampson equations, and compared values with preparative ultracentrifugation (PUC) LDL-C overall and with a special interest in the low LDL-C/high triglycerides subgroup. There were 242 patients contributing 921 observations. Overall median LDL-C differences between estimates and PUC were small: Friedewald, 0.00 (25th, 75th: -0.10, 0.08) mmol/L [0 (-4, 3) mg/dL]; Martin/Hopkins, 0.02 (-0.08, 0.10) mmol/L [1 (-3, 4) mg/dL]; and Sampson, 0.05 (-0.03, 0.15) mmol/L [2 (-1, 6) mg/dL]. In the subgroup with estimated LDL-C <1.8 mmol/L (<70 mg/dL) and triglycerides 1.7-4.5 mmol/L (150-399 mg/dL), the Friedewald equation underestimated LDL-C with a median difference versus PUC of -0.25 (-0.33, -0.10) mmol/L [-10 (-13, -4) mg/dL], whereas the median difference by Martin/Hopkins was 0.00 (-0.08, 0.10) mmol/L [0 (-3, 4) mg/dL] and by Sampson was -0.06 (-0.13, 0.00) mmol/L [-2 (-5, 0) mg/dL]. In this subgroup, the proportion of LDL-C observations <1.8 mmol/L (<70 mg/dL) that were correctly classified compared with PUC was 71.4% by Friedewald vs. 100.0% by Martin/Hopkins and 93.1% by Sampson.
Conclusion: In European patients with dyslipidaemia receiving a CETP inhibitor, we found improved LDL-C accuracy using contemporary equations vs. the Friedewald equation, and the greatest accuracy was observed with the Martin/Hopkins equation.
Registration: ClinicalTrials.gov, NCT01970215.
Keywords: Accuracy; Cholesterol ester transfer protein inhibition; Friedewald equation; Low-density lipoprotein cholesterol; Martin/Hopkins equation; Sampson equation.
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
Figures



Similar articles
-
Accuracy of 23 Equations for Estimating LDL Cholesterol in a Clinical Laboratory Database of 5,051,467 Patients.Glob Heart. 2023 Jun 19;18(1):36. doi: 10.5334/gh.1214. eCollection 2023. Glob Heart. 2023. PMID: 37361322 Free PMC article.
-
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial.JAMA Cardiol. 2018 Aug 1;3(8):749-753. doi: 10.1001/jamacardio.2018.1533. JAMA Cardiol. 2018. PMID: 29898218 Free PMC article.
-
Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels.JAMA Netw Open. 2021 Oct 1;4(10):e2128817. doi: 10.1001/jamanetworkopen.2021.28817. JAMA Netw Open. 2021. PMID: 34709388 Free PMC article.
-
Discordance Between Standard Equations for Determination of LDL Cholesterol in Patients With Atherosclerosis.J Am Coll Cardiol. 2022 Feb 15;79(6):530-541. doi: 10.1016/j.jacc.2021.11.042. J Am Coll Cardiol. 2022. PMID: 35144744
-
Best practice for LDL-cholesterol: when and how to calculate.J Clin Pathol. 2023 Mar;76(3):145-152. doi: 10.1136/jcp-2022-208480. Epub 2023 Jan 17. J Clin Pathol. 2023. PMID: 36650044 Review.
Cited by
-
Comparison between the Friedewald, Martin and Sampson Equations and LDL-C Quantification by Ultracentrifugation in a Mexican Population.Diagnostics (Basel). 2024 Jun 13;14(12):1241. doi: 10.3390/diagnostics14121241. Diagnostics (Basel). 2024. PMID: 38928656 Free PMC article.
-
Prevention is the key.Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11;10(8):649-651. doi: 10.1093/ehjcvp/pvae090. Eur Heart J Cardiovasc Pharmacother. 2025. PMID: 39797531 Free PMC article. No abstract available.
-
Accuracy of 23 Equations for Estimating LDL Cholesterol in a Clinical Laboratory Database of 5,051,467 Patients.Glob Heart. 2023 Jun 19;18(1):36. doi: 10.5334/gh.1214. eCollection 2023. Glob Heart. 2023. PMID: 37361322 Free PMC article.
-
Machine learning-based prediction of LDL cholesterol: performance evaluation and validation.PeerJ. 2025 Apr 9;13:e19248. doi: 10.7717/peerj.19248. eCollection 2025. PeerJ. 2025. PMID: 40226546 Free PMC article.
-
Evaluation of current indirect methods for measuring LDL-cholesterol.Clin Chem Lab Med. 2025 Feb 19;63(6):1099-1108. doi: 10.1515/cclm-2025-0024. Print 2025 May 26. Clin Chem Lab Med. 2025. PMID: 39964360
References
-
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC scientific document group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–188. - PubMed
-
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 2019;139:e1082–e143. - PMC - PubMed
-
- Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet North Am Ed 2016;388:2532–2561. - PubMed
-
- Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the european atherosclerosis society consensus panel. Eur Heart J 2017;38:2459–2472. - PMC - PubMed
-
- Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med 2019;381:1557–1567. - PubMed